Study Shows HPV Vaccine Offers Sustained Protection for Women with HIV

A study published in The Lancet HIV indicates that the HPV vaccine offers robust, long-lasting protection for women living with HIV, with effectiveness sustained for up to nine years. This significant research provides crucial evidence to bolster global initiatives aimed at eradicating cervical cancer, particularly benefiting this vulnerable demographic at elevated risk of HPV infection and cervical cancer.